Business Development Summer Intern - PHD/MBA

Burlingame, CA or San Diego, CA or Remote /
Business Development /
/ Hybrid
Genesis Therapeutics is seeking a Business Development Summer Intern to help advance strategic research collaborations and/or out-licensing partnerships with major pharmaceutical companies, related to Genesis Therapeutics’ novel AI-enabled drug discovery platform.  This role may also support other Corporate Strategy initiatives. 

The candidate should have a strong understanding of drug development and the biotech/pharmaceuticals landscape.  An ideal candidate would also have prior experience across biotech business development, oncology, portfolio/R&D strategy, and/or strategy consulting.  

This role will report to the Senior Director, Business Development and Strategy and may be based at Genesis Therapeutics’ physical office in Burlingame CA in a hybrid/flexible work schedule, or remotely.  Estimated internship timing would be ~10-12 weeks (e.g., mid-June through mid-September), subject to candidate availability. 

Key Responsibilities

    • Research pharma pipelines, commercial portfolios, and key stakeholders to help identify and prioritize potential partnerships based on Genesis' strategic objectives and AI platform
    • Analyze comparable deals and collaborate with a diverse set of Genesis Therapeutics stakeholders to set objectives and draft potential terms for platform and/or asset partnerships
    • Support preparation of materials for ongoing discussions with actual/potential pharma partners, and assist other activities across end-to-end business development processes
    • Contribute to other corporate strategy initiatives (e.g., market sizing, competitive research)


    • Currently enrolled in EITHER a life sciences PhD program (e.g., bioengineering, chemistry) OR a top-tier MBA program with prior experiences in the life sciences industry
    • Familiarity with life sciences and drug development via prior roles, internships, consulting, academic research, or academic groups (e.g., life sciences consulting clubs)
    • Prior experience supporting corporate strategy and/or business development work, ideally in life sciences, including primary/secondary research and quantitative/qualitative analyses
    • Knowledge of oncology, computational small molecule drug discovery, and/or AI drug discovery platform landscape would be preferred, but not required
    • Excellent communication, listening and strong presentation skills
    • An undergraduate degree in life sciences or related field preferred
    • If remote, ability for occasional travel to San Francisco Bay Area

What We Offer

    • Competitive salary for the internship
    • Free lunches and team events if on-site  
    • The opportunity to work on challenging, high impact activities that will tangibly accelerate pharmaceutical innovation and the discovery and development of new medicines
    • One-on-one mentorship and experience to support a business-oriented career in biotech
    • Strong technical coworkers in AI, software, and chemistry, who all have a powerful mix of intellectual curiosity and humility. The team reads and discusses 1-2 engineering or chemistry papers every week to stay on top of the field and inspire new ideas
About Genesis Therapeutics
We’re a team of proven drug hunters, deep learning researchers, and software engineers interrogating unexplored chemical space to identify and develop novel candidates for undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.

Genesis Therapeutics has created the industry's most advanced molecular AI platform by combining 3D structure-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine. The company’s technology is uniquely able to address previously undruggable and data-poor targets using robust computational infrastructure that scales the AI platform on the cloud, enabling immense swaths of chemical space to be searched.

We raised a $52M series A with lead investors Rock Springs Capital and T Rowe Price; as well as lead seed investor Andreessen Horowitz. We have announced two significant, multi-target collaborations with Genentech, and most recently with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.

We are proud to be an inclusive workplace and an Equal Opportunity Employer.